AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS
Open Access
- 1 November 2005
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (11) , 1637-1647
- https://doi.org/10.1124/dmd.105.005579
Abstract
Increasing reports of time-dependent inhibition of cytochrome P450 (P450) suggest further emphasis on interpreting the consequences, either from a pharmacokinetic or toxicological perspective. Two automated, time-dependent inhibition assays with a liquid chromatography-tandem mass spectrometric endpoint are presented. The initial assay utilizes human liver microsomes, a single concentration of inhibitor, and a single preincubation time of 30 min. Phenacetin, diclofenac, S-mephenytoin, bufuralol, and midazolam are used as substrates for CYP1A2, 2C9, 2C19, 2D6, and 3A4, and the assay differentiates between reversible and irreversible inhibition. The second assay uses individual recombinant human P450s, six inhibitor concentrations, and three time points to accurately define kinact and KI. A good correlation is demonstrated between kinact/KI and partition ratio, indicating that both terms are related in describing the efficiency of enzyme inactivation. Despite the single preincubation time point of 30 min used in the initial assay, a good relationship has been found to exist between the unbound IC50 estimated from this initial screen and the kinact/KI ratio derived from the more extensive subsequent single P450 assay. The higher throughput human liver microsomal assay can therefore generate IC50 values that can be used to predict the pharmacokinetic impact on cotherapies from the estimated kinact/KI ratio, predicted human dose, and pharmacokinetics.Keywords
This publication has 32 references indexed in Scilit:
- IN VITRO DRUG INTERACTIONS OF CYTOCHROME P450: AN EVALUATION OF FLUOROGENIC TO CONVENTIONAL SUBSTRATESDrug Metabolism and Disposition, 2003
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003
- Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and QuinidineDrug Metabolism and Disposition, 2003
- Mechanism-Based Inactivation of Cytochrome P450 2B6 by a Novel Terminal Acetylene InhibitorDrug Metabolism and Disposition, 2003
- The Influence of Nonspecific Microsomal Binding on Apparent Intrinsic Clearance, and Its Prediction from Physicochemical PropertiesDrug Metabolism and Disposition, 2002
- Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymesDrug Metabolism Reviews, 2002
- Inhibition by Ticlopidine and Its Derivatives of Human Liver Cytochrome P450. Mechanism-Based Inactivation of CYP 2C19 by TiclopidinePublished by Springer Nature ,2001
- Fluorometric screening for metabolism-based drug–drug interactionsJournal of Pharmacological and Toxicological Methods, 2000
- CYP3A4 drug interactions: correlation of 10 in vitro probe substratesBritish Journal of Clinical Pharmacology, 1999
- Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugsBiochemical Pharmacology, 1995